Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Overview
Explore Liminatus Pharma, Inc. Class A Common Stock’s financial performance, market position, analyst ratings, and future outlook.
LIMN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Liminatus Pharma, Inc. Class A Common Stock (LIMN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of N/A.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.41 and a market capitalization of 438.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Mr. Chris Kim J.D., L.L.M.
3
6 Centerpointe Drive, La Palma
2025